Gilead Sciences Inc. (GILD) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Gilead Sciences Inc. (GILD)

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

123.20

-0.56 (0.45%)

as of Jun 18, 2026, 10:18:29 pm Market Open.

113 watching

BUY

Healthcare is down 2% year. He likes the devices in HC, with Stryker his top pick. Surgeries are coming back, and the company has a new suite of products coming.

BUY

Was upgraded today

It's a biopharma which as a group did very well last year. Compare that to the smaller biotechs which have not done well the past 3 years. This year, biopharma and staples have underperformed. This boasts a high free cash flow yield and has a great product cycle coming.

HOLD

Chart pattern indicating weakness in the company.
Risk lower than the past year.
$60 share price a good time to buy.

WATCH

In past years, biotech was the safe trade, but this year risk is back, so these stocks have fallen out of favour. Also, there are so many drugs in trials now and big pharma needs new product. She's looking at Gilead and Moderna, because they have low PEs and alot of drugs in development. However, the overall sector is risky.

BUY

Has long owned this, because it's a value stock and keeps raising its dividend.

WAIT

It is a biotech company well known for a cure for Hepatitis C which is off patent now. It made several acquisitions and has built out an HIV franchise. He needs to see execution on the oncology platform and elsewhere.

DON'T BUY

No new drugs or trials. Doing nothing interesting. Prefers Eli Lilly.

BUY

It was upgraded today. What an earnings report, and they increased full-year guidance. Their HIV franchise continues to drive the top and bottom lines. Long-term, they continue to expand in oncolocy treatments--their pipeline looks fine.

BUY

Likes healthcare. This pays a 4.5% dividend yield, because of the strength of their drugs. Likes their huge pipeline of drugs, spanning cell therapy, oncology and HIV. They just beat top and bottom lines and raised their 2022 guidance.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Oct 27/20, Up 6.6%)Stockchase Research Editor: Michael O’Reilly Our PAST TOP PICK with GILD has triggered its stop at $64. To remain disciplined, we recommend covering the position at this time. We will look for better opportunities.

SELL

He sold 2 years ago. "Patience required" is a polite way of saying "sell". He got tired of the same promises. Yes it's cheap, but not executing on R&D. Report on its 20B acquisition has been delayed.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Oct 27/20, Up 16.7%)Stockchase Research Editor: Michael O'Reilly Our PREVIOUS TOP PICK with GILD is progressing well. To remain disciplined, we recommend trailing up the stop (from $50) to $64 at this time.

WEAK BUY

It is a healthcare name recently valued by investors. She likes to see a more visible pipeline in companies she buys. But this is a reasonable investment in this space.

BUY

They had good news about new drugs recently, but the stock still sold off. That's a sell signal.

SELL ON STRENGTH

It's bottoming because of interest rates. Sell it at $65. You can also swap this for Bristol-Myers.

Showing 1 to 15 of 259 entries

Gilead Sciences Inc. (GILD) Frequently Asked Questions

What is Gilead Sciences Inc. stock symbol?

Gilead Sciences Inc. is a American stock, trading under the symbol GILD (previously GILD-Q on Stockchase) on the NASDAQ (GILD). It is usually referred to as NASDAQ:GILD or GILD

Is Gilead Sciences Inc. a buy or a sell?

In the last year, no analyst issued a Buy, Sell, or Hold rating on GILD (previously GILD-Q on Stockchase) on Stockchase. Read the latest expert commentary for Gilead Sciences Inc..

Is Gilead Sciences Inc. a good investment or a top pick?

Gilead Sciences Inc. was recommended as a Top Pick by Jim Cramer - Mad Money on 2020-11-13. Read the latest stock experts ratings for Gilead Sciences Inc..

Why is Gilead Sciences Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Gilead Sciences Inc..

Is Gilead Sciences Inc. worth watching?

Gilead Sciences Inc. is followed by 113 investors on Stockchase and is a trending stock that is worth watching.

What is Gilead Sciences Inc. stock price?

On 2026-06-18, Gilead Sciences Inc. (GILD) stock closed at a price of $123.20.

Most Recent Experts

Stockchase Insights

5i Research

Brian Acker, CA

Acker Finley Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

David Burrows

Barometer Capital Management

Jim Cramer - Mad Money

CNBC

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Gilead Sciences Inc. (GILD)